3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof
HK40063047BActive Publication Date: 2026-07-17SAGE THERAPEUTICS LLC
Patent Information
- Authority / Receiving Office
- HK · HK
- Patent Type
- Patents
- Current Assignee / Owner
- SAGE THERAPEUTICS LLC
- Filing Date
- 2022-04-21
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
There is a need for new compounds that act as modulators of brain excitability and are effective in treating CNS-related disorders, as existing neuroactive steroids and benzodiazepines have limitations in efficacy and specificity.
Method used
Development of 3α-hydroxy-17β-amide neuroactive steroids that selectively modulate the GABA A receptor, particularly the α4β3δ subunit composition, to treat CNS-related disorders such as depression and other conditions.
Benefits of technology
The compounds effectively modulate brain excitability and treat CNS-related disorders by enhancing or reducing neuronal activity through the GABA A receptor, providing therapeutic benefits for conditions like depression and other neurological issues.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.